Antibody Liquid Formulation Stabilization via Polysorbate 80
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Liquid pharmaceutical formulations of antibodies face challenges in maintaining long-term stability due to protein aggregation and precipitation, which can lead to reduced efficacy and safety issues during storage and administration.
Innovation Solution
A novel liquid formulation comprising an antibody with specific concentrations of glycine and sucrose, along with a surfactant like Polysorbate 80, in a citrate buffer at a pH of 5, which reduces protein aggregation and precipitation by stabilizing the antibody and maintaining its activity over time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If liquid formulation is used for antibody, then ease of administration is improved, but stability against aggregation and precipitation deteriorates
Solution Approach 1:
The patent introduces polysorbate 80 as a surfactant intermediary that adsorbs to the antibody surface and prevents aggregation by reducing surface tension and preventing protein-protein interactions. This mediator enables liquid formulation stability without requiring freeze-drying, thus maintaining ease of administration while improving stability.
Solution Approach 2:
The patent optimizes specific parameters including pH (using citrate buffer to maintain pH 3-5), ionic strength, and concentrations of stabilizing agents (glycine at 10-500 mM, sucrose at 5-20% w/v). These parameter changes create optimal conditions for antibody stability in liquid form, preventing aggregation while maintaining solubility and bioactivity.
2Reliability
If stabilizers are added to prevent aggregation, then stability is improved, but formulation complexity increases
Solution Approach 1:
The patent uses polysorbate 80 which serves multiple functions: it acts as a surfactant to prevent aggregation, a solubility enhancer to maintain antibody dissolution, and a protective agent against surface adsorption. This multi-functional approach improves stability without proportionally increasing formulation complexity.
Solution Approach 2:
The patent creates a composite formulation system combining antibody with multiple stabilizing components (surfactant polysorbate 80, buffer citrate, osmolytes glycine and sucrose). This composite approach synergistically enhances stability through multiple mechanisms acting together, achieving superior protection against aggregation compared to single additives.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation exhibits a minimal increase in high molecular weight species after storage, ensuring the antibody remains active and effective for a longer period, reducing the risk of aggregation and precipitation, and maintaining its therapeutic integrity.
Implementation Method 1
various stabilizers have been explored in the art to help decrease the degradation rates of antibodies via a preferred exclusion mechanism, leading to a layer of excess water surrounding the antibody, and forcing the protein to acquire a more compact state to minimize its surface area
Implementation Method 2
A novel liquid formulation comprising an antibody with specific concentrations of glycine and sucrose, along with a surfactant like Polysorbate 80, in a citrate buffer at a pH of 5, which reduces protein aggregation and precipitation by stabilizing the antibody
Implementation Method 3
in a citrate buffer at a pH of 5, which reduces protein aggregation and precipitation by stabilizing the antibody and maintaining its activity over time
Data Source
AI summary
The current invention relates to a new pharmaceutical formulation, in particular to a pharmaceutical formulation comprising a protein, more particularly an antibody as an active ingredient.